A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Inclusion Criteria: 1. Age ≥ 18 and ≤ 75 years, Male and female patients; 2. Diagnosis of PNH based on flow cytometry with clone size \> 10% by granulocytes; 3. Have not received complement inhibitor treatment; 4. Blood LDH values \> 1.5 ×upper limit of the normal range (ULN) ; 5. Hemoglobin level \< 10 g/dL at screening. Exclusion Criteria: 1. Hereditary or acquired complement deficiency; 2. Active primary or secondary immunodeficiency; 3. History of splenectomy, bone marrow/ hematopoietic stem cell or solid organ transplants; 4. History of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or Mycobacterium tuberculosis; 5. Patients with laboratory evidence of bone marrow failure (reticulocytes \< 100x10\^9/L, or platelets \< 30x10\^9/L or neutrophils \< 0.5x10\^9/L) ; 6. Active systemic infection within 2 weeks prior to study drug administration; 7. History of serious comorbidities that have been determined to be unsuitable for participation in the study. 8. Pregnant or Lactating women.